Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK2 | P25098 | 19/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 13/20 | 1.00 |
| ▸ | GRK5 | P34947 | 13/20 | 1.00 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 1.00 |
| ▸ | RPS6KA1 | Q15418 | 2/20 | 1.00 |
| ▸ | GRK1 | Q15835 | 5/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gsk-180736A SCHEMBL29431133 | 1.00 | GRK2 (1.00) | GRK2ROCK1GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2570028 | 0.97 | GRK2 (0.94) | GRK2ROCK1GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2570395 | 0.91 | GRK2 (0.84) | GRK2ROCK1GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2563079 | 0.91 | GRK2 (0.84) | GRK2ROCK1GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2567101 | 0.91 | GRK2 (0.84) | GRK2ROCK1GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2571059 | 0.91 | GRK2 (0.82) | GRK2ROCK1GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2569353 | 0.90 | GRK2 (0.82) | GRK2ROCK1GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2566546 | 0.90 | GRK2 (0.82) | GRK2ROCK1GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2565505 | 0.90 | GRK2 (0.82) | GRK2ROCK1GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2569551 | 0.90 | GRK2 (0.81) | GRK2ROCK1GRK5RPS6KB1RPS6KA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3843845-B1 | INHIBITION OF PROTEIN KINASES TO TREAT FRIEDREICH ATAXIA | UNIV MASSACHUSETTS (US) | 2026-03-11 | — | — | EP | claimed |
| EP-1633740-B1 | 5-(ACYLAMINO)INDAZOLE DERIVATIVES AS KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-11-09 | — | — | EP | claimed |
| US-7560467-B2 | Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | claimed |
| US-20070099944-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2007-05-03 | — | — | US | claimed |
| EP-4048809-B1 | SYSTEMS AND METHODS FOR PREDICTING THERAPEUTIC SENSITIVITY | TEMPUS AI INC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4729940-A2 | LARGE SCALE ORGANOID ANALYSIS | Tempus AI, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-3843845-B1 | INHIBITION OF PROTEIN KINASES TO TREAT FRIEDREICH ATAXIA | UNIV MASSACHUSETTS (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12522804-B2 | Method for producing pancreatic β cells | KANEKA CORPORATION (JP) | 2026-01-13 | — | — | US | disclosed |
| US-20260011445-A1 | SYSTEMS AND METHODS FOR PREDICTING THERAPEUTIC SENSITIVITY | TEMPUS AI INC (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4070098-B1 | LARGE SCALE ORGANOID ANALYSIS | TEMPUS AI INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12451250-B2 | Systems and methods for predicting therapeutic sensitivity | TEMPUS AI, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250285704-A1 | QUANTIFYING EFFECTS OF SEQUENCING VARIANCE ON CLASSIFICATION | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2025-09-11 | — | — | US | disclosed |
| US-7560467-B2 | Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560467-B2 | Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| EP-1633740-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20070099944-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2007-05-03 | — | — | US | disclosed |
| US-20070099944-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2007-05-03 | — | — | US | disclosed |
| US-20070099944-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2007-05-03 | — | — | US | disclosed |
| EP-1633740-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004112719-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260011445-A1 | SYSTEMS AND METHODS FOR PREDICTING THERAPEUTIC SENSITIVITY | BRCA1, PARP2, PARP4 | GRK2 3269/4885ROCK1 1333/4885GRK5 4085/4885 |
| US-20070099944-A1 | Chemical compounds | ROCK1, ROCK2, CIT | GRK2 165/4885ROCK1 1/4885GRK5 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.